To the extent that renal fluid and Na+ excretion can determine blood pressure and heart failure, model results can be used to assess the degree to which cardiovascular benefits SGLT2 inhibitors persist in patients with reduced GFR, and why. Here, SLC5A2 is linked to heart failure.